Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma as measured with commercially available radioimmunoassay kits.

[1]  K. Nakao,et al.  γ-Atrial natriuretic polypeptide (γANP)-derived peptides in human plasma: Cosecretion of N-terminal γANP fragment and αANP , 1988 .

[2]  S. Bloom,et al.  Increase in plasma concentrations of cardiodilatin (amino terminal pro-atrial natriuretic peptide) in cardiac failure and during recumbency. , 1988, British heart journal.

[3]  T. Benraad,et al.  A sensitive radioimmunoassay of atrial natriuretic peptide in human plasma, using a tracer with an immobilized glycouril agent. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[4]  F. Boomsma,et al.  Stability of human plasma atrial natriuretic peptide during storage at −80°C , 1993 .

[5]  N. Markandu,et al.  N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126). , 1994, Clinical science.

[6]  K. Imataka,et al.  Plasma levels of atrial natriuretic factor in patients with congestive heart failure. , 1985, The New England journal of medicine.

[7]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[8]  C. Hall,et al.  In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine. , 1995, Circulation.

[9]  N. Markandu,et al.  Concentrations of N-terminal ProANP in human plasma: evidence for ProANP (1-98) as the circulating form. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[10]  P. Koistinen,et al.  Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. , 1992, The American journal of physiology.

[11]  K. Minaker,et al.  Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. , 1992, JAMA.

[12]  D. vesely,et al.  The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. , 1989, Circulation.

[13]  A. Struthers,et al.  N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. , 1995, Circulation.

[14]  I. Tikkanen,et al.  PLASMA ATRIAL NATRIURETIC PEPTIDE IN CARDIAC DISEASE AND DURING INFUSION IN HEALTHY VOLUNTEERS , 1985, The Lancet.

[15]  P. Mathisen,et al.  Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. , 1993, Scandinavian journal of clinical and laboratory investigation.

[16]  O. Vuolteenaho,et al.  Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. , 1994, American heart journal.

[17]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[18]  J. Sundsfjord,et al.  Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. , 1988, The Journal of clinical endocrinology and metabolism.

[19]  K. Bailey,et al.  Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.

[20]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.